The goal of this study is to test the effectiveness of a new, smartphone-based digital IBS treatment program. With your help, we will be able to find more convenient, effective, and efficient way to treat symptoms experienced due to IBS.
If you decide to join this study, you will be asked to complete forms and surveys, access an application on your smartphone, and provide feedback about the program on a daily basis. Your participation in the study will be for about 68 weeks with 1 in-person or virtual visit. We estimate approximately 1 hour for the in-person or virtual activities. The study design involves an investigational IBS treatment. Your privacy will be kept secure and private. Only a “participant study number” will be used to when presenting your data to anyone outside of the EASITx Study Team. You may decide to discontinue your participation at any point in time.
You may be given the opportunity to receive state-of-the-art investigational treatment for IBS. You will also have the opportunity to provide valuable information to help advance medical care around the world.
You will be compensated up to $525 for the satisfactory completion of this study and its requirements.
Data will be pseudonymized and shared with the research sponsor to enable the development
of their digital IBS treatment program. The Sponsor hopes to use the data from this clinical trial
to eventually gain FDA approval for their IBS treatment program.
The Sponsor, metaMe Health, Inc. (222 Merchandise Mart Plaza, Suite 1230, Chicago, IL 60654), is committed to developing FDA-approved prescription digital therapeutics for the treatment of gastrointestinal conditions. They are hoping to deliver effective, safe, and affordable treatment options that patients can easily access through their smartphones.